0001493152-24-021732.txt : 20240529 0001493152-24-021732.hdr.sgml : 20240529 20240529084516 ACCESSION NUMBER: 0001493152-24-021732 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240528 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulmatrix, Inc. CENTRAL INDEX KEY: 0001574235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461821392 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36199 FILM NUMBER: 24994139 BUSINESS ADDRESS: STREET 1: 36 CROSBY DRIVE STREET 2: SUITE 100 CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 357-2333 MAIL ADDRESS: STREET 1: 36 CROSBY DRIVE STREET 2: SUITE 100 CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: Ruthigen, Inc. DATE OF NAME CHANGE: 20130411 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2024

PULMATRIX, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36199

46-1821392

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

36 Crosby Drive, Suite 100

Bedford, MA 01730

(Address of principal executive offices) (Zip Code)

(781) 357-2333

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PULM		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On May 28, 2024, Pulmatrix, Inc. (the “Company”) and MannKind Corporation, a Delaware Corporation (“MannKind”) entered into a Bill of Sale and Assignment Agreement (the “BSA”) with respect to the transfer of the Company’s Bedford, Massachusetts, R&D facility (the “R&D Facility”) to MannKind along with all leasehold improvements, laboratory equipment and other related personal property. In connection with the transfer of the R&D Facility, the Company, MannKind and Cobalt Propco 2020, LLC, a Delaware limited liability company (the “Landlord”) will enter into an Amendment to Lease and Consent to Assignment of Lease (the “Lease Assignment Agreement”) in connection with the premises (the “Premises”) that the Company leases at 36 Crosby Drive, Bedford, Massachusetts, pursuant to that certain Lease Agreement, dated as of January 7, 2022 (the “Lease Agreement”), by and between the Company and the Landlord (collectively, the “MannKind Transactions”). Pursuant to the Lease Assignment Agreement, MannKind will assume all of the Company’s obligations under the Lease Agreement, including all rent and other payments pursuant to the Lease Agreement. The transfer of the R&D Facility to MannKind is expected to close during July 2024.

In connection with the transactions contemplated by the BSA and Lease Assignment, the Company and MannKind entered into an Intellectual Property Cross License Agreement (the “IPA”). The effectiveness of the IPA and the licenses granted therein is subject to closing of the transactions contemplated by the BSA and the Lease Assignment Agreement. Pursuant to the IPA, the Company will grant to MannKind (i) an exclusive license to develop, use, manufacture, market, offer and sell its inhaled Small Particles Easily Respirable and Emitted (“iSPERSE”) formulations of Clofazimine, (ii) an exclusive license to develop, use, manufacture, market, offer and sell formulations of iSPERSE with one more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans, (iii) an exclusive license to develop, use, manufacture, market, offer and sell iSPERSE formulations of insulin, (iv) a non-exclusive license to develop, use, manufacture, market, offer and sell formulations of iSPERSE with one more active pharmaceutical ingredients for the treatment of endocrine disease in humans, and (v) a non-exclusive license to develop, use, manufacture, market, offer and sell formulations of iSPERSE with one more active pharmaceutical ingredients for the treatment of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans. Additionally, pursuant to the IPA, MannKind will grant to the Company (i) the exclusive right to develop, use, manufacture, market, offer and sell its “Cricket” single-use disposable dry powder inhaler (including all modifications or improvement thereto made by or on behalf of the Company, the “Cricket Device”) for the inhaled delivery of dihydroergotamine in any formulation whatsoever, including the Company’s PUR3100 treatment of acute migraine and (ii) a non-exclusive license to develop, use, manufacture, market, offer and sell the Cricket Device for the inhaled delivery of one more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease in humans.

Additionally, pursuant to the Master Services Agreement, by and between the Company and MannKind, MannKind shall provide certain development services to the Company, including but not limited to, activities to develop a dry powder formulation of the active pharmaceutical ingredient that the Company provides to MannKind for oral inhalation using iSPERSE.

The BSA, the IPA, the MSA and the Lease Assignment Agreement contain customary representation, warranties and indemnification provisions, as applicable, and as related to transactions of this type.

Item 8.01 Other Events

On May 29, 2024, the Company issued a press release announcing the MannKind Transactions, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated May 29, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PULMATRIX, INC.

Date: May 29, 2024	By:	/s/ Teofilo Raad
		Teofilo Raad
		Chief Executive Officer

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Cross license involves Pulmatrix iSPERSE^TM technology and MannKind’s Cricket^® inhalation device.

Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.

Master service agreement in place for MannKind to provide future iSPERSE^TM dry powder drug formulation development services to Pulmatrix.

Bedford, Mass., May 29, 2024 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).

Ted Raad, Chief Executive Officer of Pulmatrix, commented, “MannKind’s interest in iSPERSE^TM validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind’s Cricket^® device to develop the 1^st orally inhaled DHE treatment for acute migraine.”

The Company entered into a cross license with MannKind pursuant to which MannKind will grant Pulmatrix a perpetual, royalty free, exclusive license to use MannKind’s Cricket inhalation device for the inhaled delivery of PUR3100, our proprietary formulation of dihydroergotamine (DHE) with iSPERSE^TM, and a perpetual, royalty free, non-exclusive license to use MannKind’s Cricket inhalation device for the inhaled delivery of any dry powder formulation formulated for the treatment or prevention of neurological disease. As part of the cross-license, the Company will grant MannKind a perpetual, royalty free, exclusive license to formulate iSPERSE^TM with clofazimine for inhalation by humans for the treatment or prevention of infection, for the treatment or prevention of nontuberculous mycobacteria lung disease in humans, and with insulin for inhalation by humans for the treatment or prevention of diabetes. We will also grant MannKind a perpetual, royalty free, non-exclusive license to formulate iSPERSE^TM for inhalation for the treatment or prevention of endocrine disease and for inhalation for the treatment or prevention of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans (“ILD”).

As part of the transaction, MannKind will assume the lease of our Bedford, Mass., R&D facility along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory. To maintain continuity of iSPERSE^TM platform knowledge, MannKind plans to hire some members of the Pulmatrix R&D staff.

The agreements are anticipated to close in July 2024.

About Pulmatrix, Inc.

Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat central nervous system (“CNS”), respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

For more on the Company’s inhaled product candidates please visit:

https://www.pulmatrix.com/pipeline.html.

About PUR3100

PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine. The Phase 1 PUR3100 trial results were presented at the 65th Annual Meeting of the American Headache society in June 2023. Over 38 million patients suffer from migraine in the United States and there is currently no orally inhaled DHE treatment option for patients.

About iSPERSE™ Technology

Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies. iSPERSE^TM is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs. iSPERSE^TM can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.

Forward-Looking Statements

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Timothy McCarthy, CFA
917-679-9282
tim@lifesciadvisors.com

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 pulm-20240528.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pulm-20240528_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pulm-20240528_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	May 28, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 28, 2024
Entity File Number	001-36199
Entity Registrant Name	PULMATRIX, INC.
Entity Central Index Key	0001574235
Entity Tax Identification Number	46-1821392
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	36 Crosby Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	(781)
Local Phone Number	357-2333
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PULM
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pulmatrix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm pulm-20240528.xsd pulm-20240528_lab.xml pulm-20240528_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PULM", "nsuri": "http://pulmatrix.com/20240528", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "pulm-20240528.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "pulm-20240528_lab.xml" ] }, "presentationLink": { "local": [ "pulm-20240528_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://pulmatrix.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-021732-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-021732-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001574235 2024-05-28 2024-05-28 iso4217:USD shares iso4217:USD shares false 0001574235 8-K 2024-05-28 PULMATRIX, INC. DE 001-36199 46-1821392 36 Crosby Drive Suite 100 Bedford MA 01730 (781) 357-2333 false false false false Common Stock, par value $0.0001 per share PULM NASDAQ false